Log in

NASDAQ:TRVITrevi Therapeutics Stock Price, Forecast & News

$6.98
-0.63 (-8.28 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.70
Now: $6.98
$8.49
50-Day Range
$2.66
MA: $4.54
$7.62
52-Week Range
$1.33
Now: $6.98
$8.49
Volume139,300 shs
Average Volume73,476 shs
Market Capitalization$124.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVI
CUSIPN/A
CIKN/A
Phone203-304-2499

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.06 per share

Profitability

Net Income$-26,050,000.00

Miscellaneous

Employees15
Market Cap$124.55 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.

Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

How has Trevi Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TRVI stock has increased by 119.5% and is now trading at $6.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Trevi Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trevi Therapeutics.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Trevi Therapeutics.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics Inc (NASDAQ:TRVI) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.04. View Trevi Therapeutics' earnings history.

What price target have analysts set for TRVI?

1 Wall Street analysts have issued 12-month price objectives for Trevi Therapeutics' shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Trevi Therapeutics' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 157.9% from the stock's current price. View analysts' price targets for Trevi Therapeutics.

Has Trevi Therapeutics been receiving favorable news coverage?

News coverage about TRVI stock has trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trevi Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Trevi Therapeutics.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 59,700 shares, an increase of 7,362.5% from the June 15th total of 800 shares. Based on an average daily volume of 124,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.3% of the shares of the stock are short sold. View Trevi Therapeutics' Current Options Chain.

Who are some of Trevi Therapeutics' key competitors?

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Canopy Growth (CGC), AbbVie (ABBV), TapImmune (MRKR), AzurRx BioPharma (AZRX), Alibaba Group (BABA), Beyond Meat (BYND), Enterprise Products Partners (EPD), LYFT (LYFT), Mplx (MPLX) and Ovid Therapeutics (OVID).

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:
  • Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)
  • Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)
  • Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)
  • Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)
  • Dr. Amale Hawi, Sr. VP of CMC (Age 65)

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $6.98.

How big of a company is Trevi Therapeutics?

Trevi Therapeutics has a market capitalization of $124.55 million. The company earns $-26,050,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Trevi Therapeutics employs 15 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.